- Home
- MIST vs PSNL Comparison
MIST vs PSNL Comparison
Compare MIST & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIST | PSNL |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.2M | 1.4B |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MIST | PSNL |
|---|---|---|
| Price | $1.09 | $14.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $8.00 | ★ $12.20 |
| AVG Volume (30 Days) | 1.4M | ★ 4.0M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | $2,915.14 | $15.34 |
| Revenue Next Year | N/A | $41.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $4.44 |
| 52 Week High | $3.06 | $16.39 |
Technical Indicators
Market Signals| Indicator | MIST | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 39.48 | 57.32 |
| Support Level | $1.01 | $6.89 |
| Resistance Level | $1.42 | $16.39 |
| Average True Range (ATR) | 0.08 | 0.60 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 23.21 | 79.33 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.